Anavex Life Sciences' (NASDAQ:AVXL) oral drug candidate blarcamesine (ANAVEX2-73) slowed cognitive decline in a phase 2b/3 study.
Shares areup ~3%in Thursday premarket trading.
The trial was conducted in ~500 participants with early symptoms of Alzheimer's, including mild cognitive impairment and mild dementia. Patientswere randomized to receive blarcamesine or placebo once daily over 48 weeks.
Results showed clinically significant differences in ADAS-Cog13 and CDR-SB, two Alzheimer's disease assessment scales, between the treatment and placebo arms.
In addition, biomarkers of amyloid beta, a plaque found in the brains of those with Alzheimer's,indicated anti-amyloid effects of blarcamesine. Also, brain MRIs showed a significant reduction in brain volume loss in the blarcamesine-treated group.
Anavex (AVXL) said that blarcamesine "restores cellular homeostasis by targeting sigma-1 and muscarinic receptors."
CGS Price at posting:
$1.58 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)